Strain Name:

B6.129S7-Trp63tm2Brd/J

Stock Number:

003568

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Use Restrictions Apply, see Terms of Use
Homozygous mice die several hours after birth, exhibiting truncated forelimbs, absent hindlimbs, and transparent skin with a complete lack of hair follicles. Newborn heterozygotes have 50% decreased oral epithelial thickness, mildly thinner epidermis, and do not express keratin-6. Heterozygous mice show accelerated aging and decreased life span with severe skin lesions.

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names B6.129S7-Trp63tm1Brd/J    (Changed: 19-DEC-07 )
Type Congenic; Mutant Strain; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Specieslaboratory mouse
Background Strain C57BL/6
Donor Strain 129S7 via AB2.2 ES cell line
 
Donating Investigator IMR Colony,   The Jackson Laboratory

Description
Mills 1999 Nature 398:708 describes the homozygous phenotype on a mixed B6-Tyrc-Brd;129S7(129S5) background. Further, they do not distinguish between the two targeted alleles (pTV6H(90)-generated p63Brdm1 [Trp63tm1Brd] or pTV12E(60)-generated p63Brdm2 [Trp63tm2Brd]) as both "produced an identical phenotype." Homozygous mice are born alive, but die several hours after birth. No transcripts have been detected in homozygotes. They have striking developmental defects, exhibiting truncated forelimbs, absent hindlimbs, and transparent skin with a complete lack of hair follicles. Both the gross and histological appearance of internal organs is normal. Functional permeability of the skin is dramatically increased; homozygous mice lose thirty times more water than normal littermates. It is presumed that death occurs from dehydration. Heterozygous mice are viable, fertile, and do not exhibit any overt developmental defects. Newborn heterozygotes have 50% decreased oral epithelial thickness, mildly thinner epidermis, and do not express keratin-6.

Keyes et al 2005 Genes Dev 19:1986 describes the phenotype of heterozygous mice used in aging studies. They exclusively used p63Brdm2 (Trp63tm2Brd) mice on a mixed B6-Tyrc-Brd;129S7(129S5) background. Heterozygous mice show accelerated aging and decreased life span with severe lesions of the skin, tongue, rectum, cervix and cornea. Infection of the skin, subcutaneous tissues, oropharynx, and genitourinary tract are also significant. Older mice can also develop chronic nephritis which closely resembles age-related human kidney disease.

In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. This is the case for the strain above. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.

Development
The pTV12E(60) targeting vector, containing a keratin 14 promoter-driven Agouti minigene, a non-functional 3' portion of an hprt cassette, a single loxP site, a puromycin resistance gene, and a 129S5-derived DNA fragment containing Trp63 exons 5, 6 and 10, was used for gap repair gene targeting of the endogenous gene. This construct was inserted into the exon 10 region by electroporation into 129S7/SvEvBrd-derived AB2.2 embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6J-Tyrc-Brd blastocysts. The resulting chimeric males were bred to C57BL/6J-Tyrc-Brd females. Mutant mice were on a mixed B6;129 genetic background were sent to The Jackson Laboratory. Upon arrival, mutant mice were bred to C57BL/6J for more than 10 generations to generate this congenic strain.

Control Information

  Control
   Wild-type from the colony
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Related Strains

View Strains carrying other alleles of Trp63     (4 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Model with phenotypic similarity to human disease where etiologies involve orthologs. Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).
Ectrodactyly, Ectodermal Dysplasia, and Cleft Lip/Palate Syndrome 3; EEC3
Models with phenotypic similarity to human diseases where etiology is unknown or involving genes where ortholog is unknown.
Exstrophy of Bladder
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
ADULT Syndrome   (TP63)
Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate   (TP63)
Limb-Mammary Syndrome; LMS   (TP63)
Rapp-Hodgkin Syndrome; RHS   (TP63)
Split-Hand/Foot Malformation 4; SHFM4   (TP63)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Trp63tm2Brd/Trp63+

        B6.129S7-Trp63tm2Brd/J
  • taste/olfaction phenotype
  • abnormal olfactory epithelium morphology
    • at P0, fewer horizontal basal cells are present   (MGI Ref ID J:173538)
  • respiratory system phenotype
  • abnormal olfactory epithelium morphology
    • at P0, fewer horizontal basal cells are present   (MGI Ref ID J:173538)
  • craniofacial phenotype
  • abnormal olfactory epithelium morphology
    • at P0, fewer horizontal basal cells are present   (MGI Ref ID J:173538)
  • growth/size/body phenotype
  • abnormal olfactory epithelium morphology
    • at P0, fewer horizontal basal cells are present   (MGI Ref ID J:173538)

Trp63tm2Brd/Trp63tm2Brd

        B6.129S7-Trp63tm2Brd/J
  • taste/olfaction phenotype
  • abnormal olfactory system morphology
    • at P0 the extension of the ducts of the olfactory glands into the lamina propria is stunted   (MGI Ref ID J:173538)
    • abnormal olfactory epithelium morphology
      • at P0, failure of horizontal basal cells differentiation   (MGI Ref ID J:173538)
      • at P0, axon bundles are not covered over by the arching processes of basal cells   (MGI Ref ID J:173538)
      • cells with olfactory gland morphology are clustered in the olfactory epithelium superficial to the basal lamina   (MGI Ref ID J:173538)
  • respiratory system phenotype
  • abnormal olfactory epithelium morphology
    • at P0, failure of horizontal basal cells differentiation   (MGI Ref ID J:173538)
    • at P0, axon bundles are not covered over by the arching processes of basal cells   (MGI Ref ID J:173538)
    • cells with olfactory gland morphology are clustered in the olfactory epithelium superficial to the basal lamina   (MGI Ref ID J:173538)
  • craniofacial phenotype
  • abnormal olfactory epithelium morphology
    • at P0, failure of horizontal basal cells differentiation   (MGI Ref ID J:173538)
    • at P0, axon bundles are not covered over by the arching processes of basal cells   (MGI Ref ID J:173538)
    • cells with olfactory gland morphology are clustered in the olfactory epithelium superficial to the basal lamina   (MGI Ref ID J:173538)
  • growth/size/body phenotype
  • abnormal olfactory epithelium morphology
    • at P0, failure of horizontal basal cells differentiation   (MGI Ref ID J:173538)
    • at P0, axon bundles are not covered over by the arching processes of basal cells   (MGI Ref ID J:173538)
    • cells with olfactory gland morphology are clustered in the olfactory epithelium superficial to the basal lamina   (MGI Ref ID J:173538)

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Trp63tm2Brd/Trp63+

        involves: 129S7/SvEvBrd
  • mortality/aging
  • premature aging
    • mice are euthanized due to age-related health issues (skin lesions or infections, weakness, palpable lymph nodes, enlarged abdomen, hemorrhage, rectal prolapse and aberrant circling behavior) earlier than wild-type mice   (MGI Ref ID J:100483)
  • premature death
    • median life span is 95 weeks compared to 121 weeks for wild-type mice   (MGI Ref ID J:100483)
    • longevity is decreased 21.5% compared to wild-type mice   (MGI Ref ID J:100483)
  • immune system phenotype
  • enlarged lymph nodes
    • 19% of of euthanized mice exhibit palpable lymph nodes   (MGI Ref ID J:100483)
  • increased susceptibility to infection
    • mice develop chronic infections if the skin, subcutaneous tissues, oropharynx and genitourinary tract   (MGI Ref ID J:100483)
  • kidney inflammation
    • mice exhibit chronic nephritis   (MGI Ref ID J:100483)
  • uterine cervix inflammation
    • mice exhibit vaginal cervicitis   (MGI Ref ID J:100483)
  • digestive/alimentary phenotype
  • abnormal rectum morphology
    • mice exhibit lesions in the epithelium of the rectum   (MGI Ref ID J:100483)
    • rectal prolapse
      • 6% of euthanized mice exhibit rectal prolapse   (MGI Ref ID J:100483)
  • abnormal tongue epithelium morphology
    • mice exhibit lesions in the epithelium of the tongue   (MGI Ref ID J:100483)
    • mice exhibit acanthosis of the tongue epithelia   (MGI Ref ID J:100483)
  • cardiovascular system phenotype
  • hemorrhage
    • 12% of euthanized mice exhibit visible signs of hemorrhage   (MGI Ref ID J:100483)
  • reproductive system phenotype
  • abnormal uterine cervix epithelium morphology
    • mice exhibit lesions in the epithelium of the cervix   (MGI Ref ID J:100483)
  • uterine cervix inflammation
    • mice exhibit vaginal cervicitis   (MGI Ref ID J:100483)
  • renal/urinary system phenotype
  • kidney inflammation
    • mice exhibit chronic nephritis   (MGI Ref ID J:100483)
  • growth/size/body phenotype
  • abnormal tongue epithelium morphology
    • mice exhibit lesions in the epithelium of the tongue   (MGI Ref ID J:100483)
    • mice exhibit acanthosis of the tongue epithelia   (MGI Ref ID J:100483)
  • distended abdomen
    • 14% of euthanized mice exhibit enlarged abdomen   (MGI Ref ID J:100483)
  • behavior/neurological phenotype
  • circling
    • 2% of euthanized mice exhibit aberrant circling   (MGI Ref ID J:100483)
  • weakness
    • 35% of euthanized mice exhibit extreme weakness   (MGI Ref ID J:100483)
  • vision/eye phenotype
  • abnormal corneal epithelium morphology
    • mice exhibit lesions in the epithelium of the cornea of the eye   (MGI Ref ID J:100483)
    • mice exhibit corneal granulation   (MGI Ref ID J:100483)
  • craniofacial phenotype
  • abnormal tongue epithelium morphology
    • mice exhibit lesions in the epithelium of the tongue   (MGI Ref ID J:100483)
    • mice exhibit acanthosis of the tongue epithelia   (MGI Ref ID J:100483)
  • integument phenotype
  • acanthosis
    • mice exhibit acanthosis of the tongue epithelia   (MGI Ref ID J:100483)
  • alopecia
    • mice exhibit moderate alopecia   (MGI Ref ID J:100483)
  • skin lesions
    • 52% of euthanized mice exhibit skin lesions or infections mice exhibit hyperplastic epithelila and progressive skin lesions   (MGI Ref ID J:100483)
    • spontaneous skin ulceration
      • mice exhibit ulcerations with severe abscesses in the dermis that often contain bacterial inclusions   (MGI Ref ID J:100483)

Trp63tm2Brd/Trp63tm2Brd

        involves: 129S7/SvEvBrd * C57BL/6J
  • mortality/aging
  • complete neonatal lethality
    • death occurs within several hours of birth   (MGI Ref ID J:54636)
  • embryogenesis phenotype
  • abnormal primitive urogenital sinus morphology
    • at E11.5, both the mesenchyme and epithelium of the ventral UGS develop abnormally   (MGI Ref ID J:119657)
    • at E11.5, apoptosis is significantly increased in the ventral UGS epithelium, as determined by TUNEL assay and cleaved caspase-3 expression   (MGI Ref ID J:119657)
    • at E11.5, a reduction in cell proliferation is observed in the UGS mesenchyme relative to wild-type controls, as shown by BrdU staining   (MGI Ref ID J:119657)
  • absent apical ectodermal ridge
  • small limb buds
    • small and misshapen at E11.5   (MGI Ref ID J:54636)
  • umbilical hernia
    • at E18.5, homozygotes with bladder exstrophy exhibit umbilical hernia   (MGI Ref ID J:119657)
  • limbs/digits/tail phenotype
  • abnormal forelimb morphology
    • truncated   (MGI Ref ID J:54636)
    • abnormal humerus morphology
      • usually truncated, thinner than normal and deformed   (MGI Ref ID J:54636)
    • absent radius   (MGI Ref ID J:54636)
    • absent ulna
      • sometimes absent   (MGI Ref ID J:54636)
  • abnormal limb bone morphology   (MGI Ref ID J:54636)
    • abnormal humerus morphology
      • usually truncated, thinner than normal and deformed   (MGI Ref ID J:54636)
    • abnormal phalanx morphology
    • absent carpal bone
      • all are missing   (MGI Ref ID J:54636)
    • absent radius   (MGI Ref ID J:54636)
    • absent ulna
      • sometimes absent   (MGI Ref ID J:54636)
  • absent apical ectodermal ridge
  • absent hindlimb   (MGI Ref ID J:54636)
  • small limb buds
    • small and misshapen at E11.5   (MGI Ref ID J:54636)
  • skeleton phenotype
  • abnormal limb bone morphology   (MGI Ref ID J:54636)
    • abnormal humerus morphology
      • usually truncated, thinner than normal and deformed   (MGI Ref ID J:54636)
    • abnormal phalanx morphology
    • absent carpal bone
      • all are missing   (MGI Ref ID J:54636)
    • absent radius   (MGI Ref ID J:54636)
    • absent ulna
      • sometimes absent   (MGI Ref ID J:54636)
  • abnormal pelvic girdle bone morphology
    • pelvic girdle usually present but lacking ossification centers   (MGI Ref ID J:54636)
    • abnormal pubic symphysis morphology
      • at E18.5, homozygotes with bladder exstrophy exhibit absence of pubic symphysis at the midline (i.e. separation of the pubic bones)   (MGI Ref ID J:119657)
  • craniofacial phenotype
  • abnormal facial morphology
    • "abnormal facies"   (MGI Ref ID J:54636)
    • absent teeth   (MGI Ref ID J:54636)
  • homeostasis/metabolism phenotype
  • impaired skin barrier function
    • water loss occurs 30X more rapidly than in controls, a skin permeability problem   (MGI Ref ID J:54636)
  • integument phenotype
  • abnormal epidermal layer morphology
    • reduced to a single layer of flattened cells   (MGI Ref ID J:54636)
    • epithelium of tongue and oral cavity is similar to the epidermis   (MGI Ref ID J:54636)
    • absent epidermis stratum corneum   (MGI Ref ID J:54636)
    • absent epidermis stratum granulosum   (MGI Ref ID J:54636)
    • absent epidermis stratum spinosum   (MGI Ref ID J:54636)
  • abnormal hair follicle development
    • skin at birth totally lacks hair follicles   (MGI Ref ID J:54636)
  • abnormal skin condition   (MGI Ref ID J:54636)
  • abnormal skin physiology
    • epidermal development apparently stops around E9.5   (MGI Ref ID J:54636)
    • impaired skin barrier function
      • water loss occurs 30X more rapidly than in controls, a skin permeability problem   (MGI Ref ID J:54636)
  • shiny skin   (MGI Ref ID J:54636)
  • translucent skin   (MGI Ref ID J:54636)
  • renal/urinary system phenotype
  • abnormal urinary bladder morphology
    • at E18.5, 4 of 12 homozygotes display bladder exstrophy with ventral bladder- and abdominal-wall defects (with and without membrane cover)   (MGI Ref ID J:119657)
    • the remaining 8 embryos develop dilated bladders with both thin lamina propria and thin muscle layers   (MGI Ref ID J:119657)
    • at E18.5, the lamina propria is either greatly reduced or absent   (MGI Ref ID J:119657)
    • abnormal urinary bladder detrusor smooth muscle morphology
      • at E18.5, 8 of 12 homozygotes exhibit dilated bladders with thin muscle layers   (MGI Ref ID J:119657)
      • at E14.5, premature smooth-muscle differentiation is observed relative to wild-type bladders   (MGI Ref ID J:119657)
      • at E18.5, little or no smooth muscle is detected ventrally, while a thin layer of smooth muscle is retained dorsally   (MGI Ref ID J:119657)
      • dorsal smooth muscle appears disorganized and non-stratified, unlike in wild-type bladders   (MGI Ref ID J:119657)
    • abnormal urinary bladder urothelium morphology
      • at E18.5, an abnormal bladder epithelium is observed along the dorso-ventral axis, with the dorsal epithelium consisting mainly of simple cuboidal cells and the ventral epithelium consisting primarily of simple squamous cells   (MGI Ref ID J:119657)
      • the ventral urothelium is neither committed to stratification nor differentiated, whereas the dorsal urothelium is both committed and differentiated   (MGI Ref ID J:119657)
      • at E11.5, a reduction in cell proliferation is observed in the ventral bladder epithelium and in adjacent mesenchyme relative to wild-type controls, as shown by BrdU staining   (MGI Ref ID J:119657)
      • at E12.5, an increase in ventral bladder epithelial apoptosis is associated with a transient upregulation of p53 and p73 expression   (MGI Ref ID J:119657)
      • at E12.5 and E13.5, developing bladders exhibit increased mitochondrial apoptotic activity relative to wild-type controls   (MGI Ref ID J:119657)
      • absent urinary bladder urothelium
        • at E18.5, the bladder epithelium fails to differentiate into stratified transitional urothelium and remains as a single layer, unlike in wild-type controls   (MGI Ref ID J:119657)
    • distended urinary bladder
      • at E18.5, 8 of 12 homozygotes develop dilated bladders with both thin lamina propria and thin muscle layers   (MGI Ref ID J:119657)
  • reproductive system phenotype
  • abnormal reproductive system morphology
    • at E18.5, homozygotes with bladder exstrophy exhibit absence of external genitalia at the midline (i.e. bifid genitalia)   (MGI Ref ID J:119657)
    • separation of external genitalia is already noted at E11.5   (MGI Ref ID J:119657)
  • growth/size/body phenotype
  • abnormal abdominal wall morphology
    • at E18.5, 4 of 12 homozygotes display ventral abdominal wall defects   (MGI Ref ID J:119657)
  • abnormal facial morphology
    • "abnormal facies"   (MGI Ref ID J:54636)
    • absent teeth   (MGI Ref ID J:54636)
  • digestive/alimentary phenotype
  • abnormal anus morphology
    • at E18.5, homozygotes with bladder exstrophy exhibit ventral translocation of the anus   (MGI Ref ID J:119657)
  • muscle phenotype
  • abnormal urinary bladder detrusor smooth muscle morphology
    • at E18.5, 8 of 12 homozygotes exhibit dilated bladders with thin muscle layers   (MGI Ref ID J:119657)
    • at E14.5, premature smooth-muscle differentiation is observed relative to wild-type bladders   (MGI Ref ID J:119657)
    • at E18.5, little or no smooth muscle is detected ventrally, while a thin layer of smooth muscle is retained dorsally   (MGI Ref ID J:119657)
    • dorsal smooth muscle appears disorganized and non-stratified, unlike in wild-type bladders   (MGI Ref ID J:119657)
  • cellular phenotype
  • abnormal mitochondrial physiology
    • at E12.5 and E13.5, developing bladders exhibit increased mitochondrial apoptotic activity, as revealed by increased expression of the mitochondrial apoptotic mediators   (MGI Ref ID J:119657)
  • increased apoptosis
    • at E11.5, apoptosis is significantly increased in the ventral UGS epithelium, in skin overlying the urogenital tubercles, and in oral-cavity epithelium, as determined by TUNEL assay and/or cleaved caspase-3 expression   (MGI Ref ID J:119657)

Trp63tm2Brd/Trp63tm2Brd

        involves: 129S7/SvEvBrd
  • limbs/digits/tail phenotype
  • abnormal limb morphology
    • abnormal apical ectodermal ridge morphology
  • cellular phenotype
  • decreased cell proliferation   (MGI Ref ID J:100483)
  • early cellular replicative senescence
    • mice exhibit an increase in cellular senescence   (MGI Ref ID J:100483)
  • craniofacial phenotype
  • abnormal craniofacial morphology
  • muscle phenotype
  • *normal* muscle phenotype
    • proximal thigh and cloacal/perineal muscles are fully formed   (MGI Ref ID J:98439)
  • embryogenesis phenotype
  • abnormal apical ectodermal ridge morphology
  • integument phenotype
  • abnormal skin morphology
    • abnormal epidermal layer morphology
      • mice exhibit stratified epidermal layer and arrested epidermal morphogenesis   (MGI Ref ID J:100483)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Dermatology Research
Skin and Hair Texture Defects

Developmental Biology Research
Growth Defects
Limb Patterning Defects
Perinatal Lethality
      Homozygous
Skin and Hair Texture Defects

Endocrine Deficiency Research
Skin Defects

Internal/Organ Research
Kidney Defects

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Trp63tm2Brd
Allele Name targeted mutation 2, Allan Bradley
Allele Type Targeted (Null/Knockout)
Common Name(s) p63Brdm2; p63KO;
Mutation Made ByDr. Alea Mills,   Cold Spring Harbor Laboratory
Strain of Origin129S7/SvEvBrd-Hprt
ES Cell Line NameAB2.2
ES Cell Line Strain129S7/SvEvBrd-Hprt
Gene Symbol and Name Trp63, transformation related protein 63
Chromosome 16
Gene Common Name(s) AI462811; AIS; B(p51A); B(p51B); EEC3; KET; KET protein; LMS; NBP; OFC8; P73l; RHS; SHFM4; TAp63; TP53CP; TP53L; TP73L; Trp53rp1; deltaNp63; expressed sequence AI462811; p40; p51; p51/p63; p53-related protein 1; p53CP; p63; p73H;
Molecular Note An integration vector disrupts the reading frame within exon 10. Northern blot analysis on homozygous mutant animals indicates that an mRNA transcript is not produced from this allele. [MGI Ref ID J:54636]

Genotyping

Genotyping Information

Genotyping Protocols

Trp63tm1Brdtm2Brd, Separated PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Mills AA; Zheng B; Wang XJ; Vogel H; Roop DR; Bradley A. 1999. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398(6729):708-13. [PubMed: 10227293]  [MGI Ref ID J:54636]

Additional References

Trp63tm2Brd related

Cancino GI; Yiu AP; Fatt MP; Dugani CB; Flores ER; Frankland PW; Josselyn SA; Miller FD; Kaplan DR. 2013. p63 Regulates Adult Neural Precursor and Newly Born Neuron Survival to Control Hippocampal-Dependent Behavior. J Neurosci 33(31):12569-85. [PubMed: 23904595]  [MGI Ref ID J:199784]

Cheng W; Jacobs WB; Zhang JJ; Moro A; Park JH; Kushida M; Qiu W; Mills AA; Kim PC. 2006. DeltaNp63 plays an anti-apoptotic role in ventral bladder development. Development 133(23):4783-92. [PubMed: 17079275]  [MGI Ref ID J:119657]

Ferone G; Mollo MR; Thomason HA; Antonini D; Zhou H; Ambrosio R; De Rosa L; Salvatore D; Getsios S; van Bokhoven H; Dixon J; Missero C. 2013. p63 control of desmosome gene expression and adhesion is compromised in AEC syndrome. Hum Mol Genet 22(3):531-43. [PubMed: 23108156]  [MGI Ref ID J:191121]

Fessing MY; Mardaryev AN; Gdula MR; Sharov AA; Sharova TY; Rapisarda V; Gordon KB; Smorodchenko AD; Poterlowicz K; Ferone G; Kohwi Y; Missero C; Kohwi-Shigematsu T; Botchkarev VA. 2011. p63 regulates Satb1 to control tissue-specific chromatin remodeling during development of the epidermis. J Cell Biol 194(6):825-39. [PubMed: 21930775]  [MGI Ref ID J:177729]

Guo X; Keyes WM; Papazoglu C; Zuber J; Li W; Lowe SW; Vogel H; Mills AA. 2009. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 11(12):1451-7. [PubMed: 19898465]  [MGI Ref ID J:158291]

Hashimoto S; Chen H; Que J; Brockway BL; Drake JA; Snyder JC; Randell SH; Stripp BR. 2012. beta-Catenin-SOX2 signaling regulates the fate of developing airway epithelium. J Cell Sci 125(Pt 4):932-42. [PubMed: 22421361]  [MGI Ref ID J:197815]

Jacobs WB; Govoni G; Ho D; Atwal JK; Barnabe-Heider F; Keyes WM; Mills AA; Miller FD; Kaplan DR. 2005. p63 is an essential proapoptotic protein during neural development. Neuron 48(5):743-56. [PubMed: 16337913]  [MGI Ref ID J:105512]

Karni-Schmidt O; Castillo-Martin M; Shen TH; Gladoun N; Domingo-Domenech J; Sanchez-Carbayo M; Li Y; Lowe S; Prives C; Cordon-Cardo C. 2011. Distinct Expression Profiles of p63 Variants during Urothelial Development and Bladder Cancer Progression. Am J Pathol 178(3):1350-60. [PubMed: 21356385]  [MGI Ref ID J:169680]

Kerr JB; Hutt KJ; Michalak EM; Cook M; Vandenberg CJ; Liew SH; Bouillet P; Mills A; Scott CL; Findlay JK; Strasser A. 2012. DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa. Mol Cell 48(3):343-52. [PubMed: 23000175]  [MGI Ref ID J:191005]

Keyes WM; Vogel H; Koster MI; Guo X; Qi Y; Petherbridge KM; Roop DR; Bradley A; Mills AA. 2006. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci U S A 103(22):8435-40. [PubMed: 16714381]  [MGI Ref ID J:110204]

Keyes WM; Wu Y; Vogel H; Guo X; Lowe SW; Mills AA. 2005. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev 19(17):1986-99. [PubMed: 16107615]  [MGI Ref ID J:100483]

Koster MI; Dai D; Roop DR. 2007. Conflicting roles for p63 in skin development and carcinogenesis. Cell Cycle 6(3):269-73. [PubMed: 17224652]  [MGI Ref ID J:121626]

Koster MI; Kim S; Huang J; Williams T; Roop DR. 2006. TAp63alpha induces AP-2gamma as an early event in epidermal morphogenesis. Dev Biol 289(1):253-61. [PubMed: 16324689]  [MGI Ref ID J:104213]

Kurita T; Cunha GR; Robboy SJ; Mills AA; Medina RT. 2005. Differential expression of p63 isoforms in female reproductive organs. Mech Dev 122(9):1043-55. [PubMed: 15922574]  [MGI Ref ID J:100707]

Kurita T; Medina RT; Mills AA; Cunha GR. 2004. Role of p63 and basal cells in the prostate. Development 131(20):4955-64. [PubMed: 15371309]  [MGI Ref ID J:93615]

Kurita T; Mills AA; Cunha GR. 2004. Roles of p63 in the diethylstilbestrol-induced cervicovaginal adenosis. Development 131(7):1639-49. [PubMed: 14998922]  [MGI Ref ID J:91853]

Laurikkala J; Mikkola ML; James M; Tummers M; Mills AA; Thesleff I. 2006. p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development 133(8):1553-63. [PubMed: 16524929]  [MGI Ref ID J:107400]

Lee S; Kong Y; Weatherbee SD. 2013. Forward genetics identifies Kdf1/1810019J16Rik as an essential regulator of the proliferation-differentiation decision in epidermal progenitor cells. Dev Biol 383(2):201-13. [PubMed: 24075906]  [MGI Ref ID J:203995]

Li Q; Sambandam SA; Lu HJ; Thomson A; Kim SH; Lu H; Xin Y; Lu Q. 2011. 14-3-3sigma and p63 play opposing roles in epidermal tumorigenesis. Carcinogenesis 32(12):1782-8. [PubMed: 21926108]  [MGI Ref ID J:178010]

Livera G; Petre-Lazar B; Guerquin MJ; Trautmann E; Coffigny H; Habert R. 2008. p63 null mutation protects mouse oocytes from radio-induced apoptosis. Reproduction 135(1):3-12. [PubMed: 18159078]  [MGI Ref ID J:133456]

Lo Iacono N; Mantero S; Chiarelli A; Garcia E; Mills AA; Morasso MI; Costanzo A; Levi G; Guerrini L; Merlo GR. 2008. Regulation of Dlx5 and Dlx6 gene expression by p63 is involved in EEC and SHFM congenital limb defects. Development 135(7):1377-88. [PubMed: 18326838]  [MGI Ref ID J:135784]

Mardaryev AN; Gdula MR; Yarker JL; Emelianov VN; Poterlowicz K; Sharov AA; Sharova TY; Scarpa JA; Chambon P; Botchkarev VA; Fessing MY. 2014. p63 and Brg1 control developmentally regulated higher-order chromatin remodelling at the epidermal differentiation complex locus in epidermal progenitor cells. Development 141(1):101-11. [PubMed: 24346698]  [MGI Ref ID J:206588]

Melino G. 2011. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 18(9):1487-99. [PubMed: 21760596]  [MGI Ref ID J:203617]

Mikkola ML; Costanzo A; Thesleff I; Roop DR; Koster MI. 2010. Treasure or artifact: a decade of p63 research speaks for itself. Cell Death Differ 17(1):180-3; author reply 184-6. [PubMed: 19876067]  [MGI Ref ID J:169431]

Moretti F; Marinari B; Lo Iacono N; Botti E; Giunta A; Spallone G; Garaffo G; Vernersson-Lindahl E; Merlo G; Mills AA; Ballaro C; Alema S; Chimenti S; Guerrini L; Costanzo A. 2010. A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias. J Clin Invest 120(5):1570-7. [PubMed: 20424325]  [MGI Ref ID J:161645]

Moretto MM; Lawlor EM; Khan IA. 2010. Lack of Interleukin-12 in p40-Deficient Mice Leads to Poor CD8+ T-Cell Immunity against Encephalitozoon cuniculi Infection. Infect Immun 78(6):2505-11. [PubMed: 20308292]  [MGI Ref ID J:159863]

Murashima A; Miyagawa S; Ogino Y; Nishida-Fukuda H; Araki K; Matsumoto T; Kaneko T; Yoshinaga K; Yamamura K; Kurita T; Kato S; Moon AM; Yamada G. 2011. Essential roles of androgen signaling in Wolffian duct stabilization and epididymal cell differentiation. Endocrinology 152(4):1640-51. [PubMed: 21303954]  [MGI Ref ID J:173864]

Murray-Zmijewski F; Lane DP; Bourdon JC. 2006. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 13(6):962-72. [PubMed: 16601753]  [MGI Ref ID J:126410]

Packard A; Schnittke N; Romano RA; Sinha S; Schwob JE. 2011. {Delta}Np63 regulates stem cell dynamics in the Mammalian olfactory epithelium. J Neurosci 31(24):8748-59. [PubMed: 21677159]  [MGI Ref ID J:173538]

Perez-Losada J; Wu D; DelRosario R; Balmain A; Mao JH. 2005. p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo. Oncogene 24(35):5521-4. [PubMed: 16007185]  [MGI Ref ID J:100784]

Radoja N; Guerrini L; Lo Iacono N; Merlo GR; Costanzo A; Weinberg WC; La Mantia G; Calabro V; Morasso MI. 2007. Homeobox gene Dlx3 is regulated by p63 during ectoderm development: relevance in the pathogenesis of ectodermal dysplasias. Development 134(1):13-8. [PubMed: 17164413]  [MGI Ref ID J:117075]

Romano RA; Smalley K; Magraw C; Serna VA; Kurita T; Raghavan S; Sinha S. 2012. DeltaNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development 139(4):772-82. [PubMed: 22274697]  [MGI Ref ID J:181275]

Rouleau M; Medawar A; Hamon L; Shivtiel S; Wolchinsky Z; Zhou H; De Rosa L; Candi E; de la Forest Divonne S; Mikkola ML; van Bokhoven H; Missero C; Melino G; Puceat M; Aberdam D. 2011. TAp63 is important for cardiac differentiation of embryonic stem cells and heart development. Stem Cells 29(11):1672-83. [PubMed: 21898690]  [MGI Ref ID J:190202]

Talos F; Wolff S; Beyer U; Dobbelstein M; Moll UM. 2010. Brdm2 - an aberrant hypomorphic p63 allele. Cell Death Differ 17(1):184-186. [PubMed: 20161489]  [MGI Ref ID J:169428]

Valasek P; Evans DJ; Maina F; Grim M; Patel K. 2005. A dual fate of the hindlimb muscle mass: cloacal/perineal musculature develops from leg muscle cells. Development 132(3):447-58. [PubMed: 15653949]  [MGI Ref ID J:98439]

Wolff S; Talos F; Palacios G; Beyer U; Dobbelstein M; Moll UM. 2009. The alpha/beta carboxy-terminal domains of p63 are required for skin and limb development. New insights from the Brdm2 mouse which is not a complete p63 knockout but expresses p63 gamma-like proteins. Cell Death Differ 16(8):1108-17. [PubMed: 19300453]  [MGI Ref ID J:164185]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2525.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We willfulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3283.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We willfulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Control Information

  Control
   Wild-type from the colony
   000664 C57BL/6J
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.6)